Peptide LexiconAll compounds

Caspofungin: The First Echinocandin, a Six-Amino-Acid Ring Against Candida and Aspergillus — What It Is and What Its Label Shows

Caspofungin was the first echinocandin antifungal approved in the US, in 2001. Chemically it is a modified fungal natural product — a small amino-acid ring with a long lipid chain. It stops Candida and Aspergillus from building a wall sugar that people lack, and hospitals give it by drip for Candida infections, invasive aspergillosis and suspected fungal infection in people with low white-cell counts.

FDA-approved (since 2001)Antifungal (echinocandin)Intravenous infusion only

Caroline S · Published 2026-11-12

Length

Cyclic hexapeptide core plus a dimethyl-myristoyl side chain — the label's chemical name is built on pneumocandin B0; caspofungin acetate is C52H88N10O15·2C2H4O2, formula weight 1,213.42 (label)

Sequence

Not a simple linear sequence: the label's chemical name lists modified ornithines (a 4-hydroxy and an aminoethylamino-substituted ornithine, and a 3-hydroxy-ornithine) on the pneumocandin B0 ring

Origin

Semisynthetic: made from a fermentation product of the fungus Glarea lozoyensis (label). First US approval 2001-01-26, Cancidas (Merck, NDA 021227)

Last reviewed

2026-11-12

What is it good for?

Treating Candida bloodstream infection and Candida infections of the abdomen and pleural space, Candida infection of the oesophagus, and invasive aspergillosis in people whose disease did not respond to, or who could not tolerate, other antifungals — and as empirical treatment of presumed fungal infection in people with fever and very low neutrophil counts (label). It is a hospital medicine given by intravenous infusion.

Illustration: A volumetric flask with pale green liquid and a coiled white and deep green molecular model on a white.
Illustration

What it is

Caspofungin was the first echinocandin antifungal the FDA approved. The US label calls it "a semisynthetic lipopeptide (echinocandin) compound synthesized from a fermentation product of Glarea lozoyensis." It was the first of the four echinocandins approved in the United States, on 26 January 2001 as Merck's Cancidas.

Like the rest of its class, it is a peptide only in a chemist's sense. The label's chemical name describes a modified pneumocandin B0 — a natural product of the fungus — carrying modified ornithines in place of ordinary amino acids. Caspofungin acetate's empirical formula is C52H88N10O15·2C2H4O2, formula weight 1,213.42.

How it works

The label gives the mechanism in its microbiology section: caspofungin inhibits the synthesis of beta (1,3)-D-glucan, "an essential component of the cell wall of susceptible Aspergillus species and Candida species," and that polymer "is not present in mammalian cells."

Resistance is recorded there too: treatment failures have been traced to changes in the enzyme's Fks subunits, coded by the fks1 and fks2 genes, which raise the concentration needed to inhibit the fungus.

What the label's trials show

Use (label) Trial design Result
Fever with very low neutrophils (empirical) Double-blind, 1,111 patients, vs AmBisome 3 mg/kg/day Overall favourable response 190/556 (33.9%) vs 181/539 (33.7%); difference 0.2, 95.2% CI −5.6 to 6.0
Candidemia and other invasive Candida Randomised, double-blind, 239 enrolled, vs amphotericin B deoxycholate Favourable at end of IV therapy 81/109 (74.3%) vs 78/115 (67.8%); 7.5, CI −5.4 to 20.3
Oesophageal candidiasis Randomised, double-blind, non-inferiority, vs IV fluconazole 200 mg/day Favourable 66/81 (81.5%) vs 80/94 (85.1%); −3.6, 95% CI −14.7 to 7.5
Invasive aspergillosis after other drugs Open-label, no comparator, 69 enrolled, 63 evaluable Favourable response 26/63 (41%); 26/52 (50%) if treated more than 7 days

What the table does and does not show, in the label's own terms. In the first three trials the confidence intervals cross zero, so they support similar performance to the comparator, not superiority. The aspergillosis result has no control arm: among patients refractory to earlier drugs the favourable rate was 19 of 53 (36%), among those intolerant of them 7 of 10 (70%).

The label also records a relapse signal in the oesophageal trial. At day 28 after treatment, 18 of 64 (28.1%) on caspofungin had relapsed against 12 of 72 (16.7%) on fluconazole — a difference the label describes as not statistically significant. In the patients who also had candidiasis of the mouth and throat, day-14 relapse was 17/40 (42.5%) vs 7/53 (13.2%). The label adds that caspofungin "has not been approved for the treatment of oropharyngeal candidiasis."

Doses on the label

These are the label's figures, reported as published; a patient's dose is decided by the clinicians treating them.

Group (label) Dose
Adults, most indications 70 mg loading dose on day 1, then 50 mg once daily
Adults, oesophageal candidiasis 50 mg once daily, no loading dose
Adults, moderate liver impairment 35 mg once daily (with a 70 mg loading dose where appropriate)
Children 3 months to 17 years 70 mg/m² on day 1, then 50 mg/m² daily; never above 70 mg

The label raises the daily dose to 70 mg in adults taking rifampin and says an increase may be considered with nevirapine, efavirenz, carbamazepine, dexamethasone or phenytoin. Every dose is a slow intravenous infusion over about an hour.

In the body

The label describes plasma levels falling in phases: a short early phase, a main phase with a half-life of 9 to 11 hours, and a longer phase of 40 to 50 hours. About 97% is bound to albumin, and distribution into tissues rather than excretion drives the early fall — about 92% of a radiolabelled dose had moved into tissues by 36–48 hours. The molecule also breaks open on its own in the body, forming an open-ring peptide the label names L-747969.

Safety

The label's warnings are hypersensitivity — anaphylaxis, possible histamine-type reactions, and cases of Stevens-Johnson syndrome and toxic epidermal necrolysis, some fatal — and liver effects, from enzyme rises to isolated cases of hepatitis and liver failure. A separate warning covers raised liver enzymes with cyclosporine.

The most common adverse reactions in adults (10% or more) were diarrhoea, fever, raised liver enzymes, raised alkaline phosphatase and low potassium. No long-term animal studies of cancer risk have been performed, the label states; its genetic-toxicity tests were negative.

Where it stands

  • Approved in the US since 2001-01-26 (Cancidas, Merck, NDA 021227).
  • Brand: Drugs@FDA lists that application as discontinued (read 2026-11-12). Merck's label in the FDA label database carries an effective date of 2024-10-11.
  • Other products: Fresenius Kabi's application (NDA 206110) and generics from Gland, Areva and Hangzhou Zhongmei are listed as prescription products; four further generic applications are discontinued.
  • Research record: PubMed indexes 4,225 records, 55 tagged as randomised controlled trials; ClinicalTrials.gov returns 99 records (2026-11-12).

The four approved members of the class are set side by side in the echinocandins entry, and the closest single comparison is micafungin, which beat caspofungin's success rate numerically but not decisively in its own label trial. The same ring-plus-fatty-tail design turns up in the bacterial-membrane antibiotic daptomycin and in surfactin, a soil-bacterium lipopeptide. For a contrast with an antibiotic that attacks a peptide-crosslinked wall rather than a sugar one, see the peptidoglycan entry.

Caspofungin was also the comparator in the trial behind the once-weekly echinocandin: the library's rezafungin entry gives that trial's results.

What the research shows

Treats candidemia and other invasive Candida infections

FDA-approved indication; randomised double-blind trial against amphotericin B: favourable response 81/109 (74.3%) vs 78/115 (67.8%) at the end of IV therapy (Cancidas label, Table 11)

Empirical therapy in febrile neutropenia

FDA-approved indication; double-blind trial in 1,111 patients against AmBisome: overall favourable response 33.9% vs 33.7% (Cancidas label, Table 9)

Treats oesophageal candidiasis

FDA-approved indication; randomised double-blind non-inferiority trial against IV fluconazole: 66/81 (81.5%) vs 80/94 (85.1%) (Cancidas label, Table 12)

Treats invasive aspergillosis after other drugs failed

FDA-approved indication on an open-label study with no comparator arm: favourable response in 26 of 63 patients (41%) (Cancidas label, section 14.4)

Bars show how much of the evidence is in humans, not how well anything works.

Where it stands

United States

Approved since 2001-01-26. Drugs@FDA lists Merck's Cancidas application (NDA 021227) as discontinued; four other applications — Fresenius Kabi's NDA 206110 and generics from Gland, Areva and Hangzhou Zhongmei — are listed as prescription products, and four more as discontinued (Drugs@FDA via openFDA, 2026-11-12).

How it is given

Slow intravenous infusion over about one hour; not as a bolus; not in dextrose-containing fluids (label).

Published record

PubMed: 4,225 records for caspofungin, 55 tagged as randomised controlled trials; ClinicalTrials.gov: 99 records mention it (2026-11-12).

Frequently asked questions

Is caspofungin a peptide?

At its core, yes. The label calls it a semisynthetic lipopeptide: a ring of amino acids — several of them modified ornithines — with a fatty side chain attached. It is made by chemically changing a natural product from a fungus, not by joining ordinary amino acids.

What is caspofungin used for?

The label lists Candida bloodstream infection and Candida infections of the abdomen and pleural space, Candida infection of the oesophagus, invasive aspergillosis in people for whom other antifungals failed or were not tolerated, and presumed fungal infection in people with fever and very low neutrophil counts. It is given in hospital by intravenous infusion.

How does caspofungin work?

It blocks the enzyme that builds beta (1,3)-D-glucan, a sugar polymer in the cell wall of Candida and Aspergillus. People have no such polymer, the label points out, so the drug's target exists only in the fungus.

What is the difference between caspofungin and micafungin?

Both are echinocandins with the same target. They are made from different fungal natural products, and their labels differ: caspofungin carries an invasive aspergillosis indication and an empirical-therapy indication in febrile neutropenia; micafungin's label instead carries prevention of Candida infection in stem-cell transplant patients.

What are caspofungin's main warnings?

Two groups of warnings. Allergic: anaphylaxis, histamine-type reactions and rare severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis), some fatal. Liver: enzyme rises, isolated hepatitis or liver failure, and a separate caution about combining it with cyclosporine. The hospital team decides on monitoring.

Is Cancidas still sold?

Drugs@FDA lists Merck's Cancidas application as discontinued as of 12 November 2026, while generic caspofungin from several manufacturers is listed as a prescription product. Merck's label in the FDA label database carries an effective date of 11 October 2024.